Reply to Schramm, L. Comment on “Li et al. BDP1 Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study. Diagnostics 2021, 11, 2364”

Affiliations

Xiaoqing Li: Department of Oncology, The People’s Hospital of Bishan District, Chongqing 402760, China
Lan Sun: Department of Oncology, The People’s Hospital of Bishan District, Chongqing 402760, China
Andres Stucky: Department of Otolaryngology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
Lingli Tu: Department of Otolaryngology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
Jin Cai: Department of Oral and Maxillofacial Surgery, Zhuhai People’s Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai 519000, China
Xuelian Chen: Department of Otolaryngology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
Zhongjun Wu: Department of Oncology, The People’s Hospital of Bishan District, Chongqing 402760, China
Xuhong Jiang: Department of Health Management, Zhuhai People’s Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai 519000, China
Shengwen Calvin Li: Neuro-Oncology and Stem Cell Research Laboratory, Center for Neuroscience Research, CHOC Children’s Research Institute, Children’s Hospital of Orange County (CHOC), 1201 West La Veta Ave., Orange, CA 92868-3874, USA

Abstract

We thank Professor Laura Schramm for her comment on the history and clarification of BDP1 nomenclature, her contribution to gene cloning [...]